|Day's Range||99.25 - 100.15|
|52 Week Range||70.68 - 101.40|
|PE Ratio (TTM)||20.72|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Wall Street is interested in the companies that help drugmakers research and develop drugs. These...
Among public companies in this industry, this one earns our very attractive rating and leads the group in return on invested capital (ROIC), the key driver of shareholder value.
Goldman Sachs analyst Robert Jones continues to see Icon PLC (NASDAQ: ICLR ) shares undervalued as he added the pharmaceutical company to America’s Conviction List. Jones has a Buy rating on the stock ...